Recombinant Viral RSV Active Src Protein, CF

The approximate molecular weight is 85 kDa and the average purity is 90%.

• Reactivity: V
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Viral RSV Active Src Protein, CF Summary

• Details of Functionality: The specific activity of Src is typically 99-133 nmol/min/mg using a synthetic peptide substrate (KVEKIGEGTYGVVYK).
• Source: Spodoptera frugiperda, Sf 9 (baculovirus)-derived viral Src protein
• Accession #: M11753
• N-terminal Sequence: Using an N-terminal GST tag
• Protein/Peptide Type: Recombinant Proteins
• Gene: src
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• SDS-PAGE: 83 kDa.

Packaging, Storage & Formulations

• Storage: This product is stable at ≤ ‑70 °C for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.
• Buffer: Supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, and 25% Glycerol.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.
• Assay Procedure:
  • Active Kinase - Active Src (0.1 μg/μL) diluted with Kinase Dilution Buffer IV and assayed as outlined in Figure 2. Note: These are suggested working dilutions. Optimal dilutions should be determined by each laboratory for each application.
  • Kinase Assay Buffer II - 25 mM MOPS, pH 7.2, 12.5 mM beta -glycerolphosphate, 20 mM MgCl₂, 12.5 mM MnCl₂ 5 mM EGTA, 2 mM EDTA. Add fresh DTT prior to use to a final concentration of 250 μM.
  • Kinase Dilution Buffer IV - Kinase Assay Buffer II diluted at a 1:4 ratio (5X dilution) with 50 ng/μL BSA solution.
  • 10 mM ATP Stock Solution - Prepare the ATP Stock Solution by dissolving 55 mg of ATP in 10 mL of Kinase Assay Buffer II. Store 200 μL aliquots at ≤ -20 °C.
  • [³³P]-ATP Assay Cocktail - Prepare 250 μM [³³P]-ATP Assay Cocktail in a designated radioactive work area by combining 150 μL of 10 mM ATP Stock Solution, 100 μL of [³³P]-ATP (1 mCi/100 μL), and 5.75 mL of Kinase Assay Buffer II. Store 150 μL aliquots at ≤ -20 °C.
  • Substrate - Src synthetic peptide substrate (KVEKIGEGTYGVVYK) diluted in distilled or deionized water to a final concentration of 1 mg/mL.
  1. Thaw the [³³P]-ATP Assay Cocktail in a shielded container in a designated radioactive work area.
  2. Thaw the Active Src, Kinase Assay Buffer II, Substrate, and Kinase Dilution Buffer IV on ice.
  3. In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μL.
     a. Diluted Active Src: 10 μL
     b. Substrate at 1 mg/mL: 5 μL
     c. Distilled or deionized water (2-8 °C): 5 μL
  4. Set up the blank control as outlined in Step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled or deionized water.
  5. Initiate the reaction by the addition of 5 μL [³³P]-ATP Assay Cocktail, bringing the final volume up to 25 μL. Incubate the mixture in a water bath at 30 °C for 15 minutes.
  6. After the 15 minute incubation period, terminate the reaction by spotting 20 μL of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
  7. Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (add 10 mL of phosphoric acid to 990 mL and make a 1 liter solution with distilled or deionized water) with constant gentle stirring. It is recommended that the strips be washed a total of three times for approximately 10 minutes each.
  8. Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
  9. Determine the corrected cpm by removing the blank control value (see Step 4) for each sample and calculate the kinase specific activity as outlined below:
     
     
     Calculation of [³³P]-ATP Specific Activity (SA) (cpm/pmol)
     Specific Activity (SA) = cpm for 5 μL [³³P]-ATP/pmol of ATP (in 5 μL of a 250 μM ATP stock solution; i.e. 1250 pmol)
     
     Calculation of Kinase Specific Activity (SA) (pmol/minutes/μg or nmol/minutes/mg)
     Corrected cpm from reaction / [(SA of ³³P-ATP in cpm/pmol) x (Reaction time in minutes) x (Enzyme amount in μg or mg)] x [(Reaction volume) / (Spot Volume)]

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Viral RSV Active Src Protein, CF

• ASV
• c-Src
• EC 2.7.10
• EC 2.7.10.2
• pp60c-src
• Rous sarcoma
• RSVgp4
• Src
• tyrosine kinase pp60c-src
• tyrosine-protein kinase SRC-1
• v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
• v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)

Background

The non-receptor tyrosine kinase Src was originally identified as a transforming protein of the Rous sarcoma virus that had enzymatic ability to phosphorylate tyrosine in protein substrates (1). The proto-oncogene c-Src is the cellular homologue of viral Src (v-Src) and the founding member of the Src family kinases. c-Src is over-expressed and activated in a large number of human maligancies and has been linked to the development of cancer and progression to distant metastases (2). In addition to increasing cell proliferation, a key role of c-Src in cancer seems to be the ability to promote invasion and motility, functions that might contribute to tumor progression.

Although v-Src and c-Src share 88% amino acid identity, v-Src, unlike c-Src, is constitutively active mainly because it lacks a crucial c-terminal negative-regulatory region (3). As a result, v-Src is missing a tyrosine residue (Y530 in human c-Src) that upon phosphorylation contributes to c-Src assuming an inactive conformation.

1. Collett, M.S. et al. (1978) Proc. Natl. Acad. Sci. USA 75:2021.
2. Jacobs, C. et al. (1983) Cancer Res. 43:1696.
3. Yeatman, T.J. (2004) Nat. Rev. Cancer 4:470.

Bioinformatics

• Gene Symbol: src
• Uniprot:
  • M11753(Viral)